跳转至内容
Merck
所有图片(1)

主要文件

查看所有文档

SML0132

Sigma-Aldrich

醋酸兰瑞肽

≥98% (HPLC)

别名:

3-(2-萘基)-D-丙氨酰基-L-半胱氨酰基-L-酪氨酸-D-色氨酸-L-赖氨酰基-L-戊酰基-L-半胱氨酰-L-苏氨酸酰胺环状(2→7)-乙酸二硫, BIM-23014C, 醋酸血管肽素

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C54H69N11O10S2 · xC2H4O2
CAS号:
127984-74-1
分子量:
1096.32 (free base basis)
分類程式碼代碼:
12352200
PubChem物質ID:
329825182
NACRES:
NA.25

品質等級

100

化驗

≥98% (HPLC)

形狀

powder

顏色

white to off-white

運輸包裝

wet ice

儲存溫度

−20°C

SMILES 字串

CC(O)=O.CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)NC(=O)[C@H](N)Cc5ccc6ccccc6c5

InChI

1S/C54H69N11O10S2.C2H4O2/c1-29(2)45-54(75)63-44(53(74)65-46(30(3)66)47(57)68)28-77-76-27-43(62-48(69)38(56)23-32-15-18-33-10-4-5-11-34(33)22-32)52(73)60-41(24-31-16-19-36(67)20-17-31)50(71)61-42(25-35-26-58-39-13-7-6-12-37(35)39)51(72)59-40(49(70)64-45)14-8-9-21-55;1-2(3)4/h4-7,10-13,15-20,22,26,29-30,38,40-46,58,66-67H,8-9,14,21,23-25,27-28,55-56H2,1-3H3,(H2,57,68)(H,59,72)(H,60,73)(H,61,71)(H,62,69)(H,63,75)(H,64,70)(H,65,74);1H3,(H,3,4)/t30-,38-,40+,41+,42-,43+,44?,45+,46+;/m1./s1

InChI 密鑰

DEXPIBGCLCPUHE-HPDHVNDUSA-N

應用

乙酸兰瑞肽已被用作抑制剂，以测试野生型小鼠中生长激素/甲状腺激素信号转导对硫化氢调节的可变性。

生化／生理作用

醋酸兰瑞肽是一种生长抑素类似物，是生长抑素受体SRIF-1 sst2亚型的选择性激动剂，对sst2的结合亲和力为0.8 nM，对sst5的结合亲和力为5.2 nM，对sst3的结合亲和力为100 nM，对于SRIF-2亚型sst1和sst4受体的结合亲和力为1000 nM以上。它在临床上可用于肢端肥大症和神经内分泌肿瘤所引起的症状的治疗，并且在最近的研究中还可以用于抑制肿瘤的生长，并显示出对非内分泌肿瘤的活性。

象形圖

Health hazard
GHS08

訊號詞

Warning

危險聲明

H361

防範說明

P281

危險分類

Repr. 2

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

从最新的版本中选择一种：

分析证书(COA)

Lot/Batch Number
096M4745V
104M4712V
091M4723V

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Lucas Sidéris et al.
The oncologist, 17(6), 747-755 (2012-05-26)
For decades, somatostatin analogs (including octreotide and lanreotide) have been indicated for relief of the symptoms of flushing, diarrhea, and wheezing associated with secretory neuroendocrine tumors (NETs). Recently, it has been suggested that somatostatin analogs may provide direct and indirect
Nancy M Gardner-Roehnelt
Clinical journal of oncology nursing, 16(1), 56-64 (2012-02-03)
Although neuroendocrine tumors (NETs) have been recognized as a family of complex malignancies since 1907, major progress has been made only in the past 20 years in understanding and managing the disease. The detection and reported incidence of NETs have
Christos Toumpanakis et al.
Seminars in oncology, 40(1), 56-68 (2013-02-09)
Somatostatin analogs (SA) are the standard of care for controlling symptoms of patients with functional gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs). SA control symptoms in more than 70% of patients with carcinoid syndrome. Similar results are obtained in patients with functional, hormone-secreting
Martyn E Caplin et al.
The New England journal of medicine, 371(3), 224-233 (2014-07-12)
Somatostatin analogues are commonly used to treat symptoms associated with hormone hypersecretion in neuroendocrine tumors; however, data on their antitumor effects are limited. We conducted a randomized, double-blind, placebo-controlled, multinational study of the somatostatin analogue lanreotide in patients with advanced
Omid Fotouhi et al.
The Journal of clinical endocrinology and metabolism, 101(10), 3616-3627 (2016-07-28)
Somatostatin analogs are established in the treatment of neuroendocrine tumors (NETs) including small intestinal NET; however, the molecular mechanisms are not well known. Here, we examined the direct effects of lanreotide in NET cell line models. The cell lines HC45
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门